Returning from Boston, my shock about this news was soon followed by an overwhelming feeling of fear and despair. When I returned home, I looked at the newly arrived device sitting in my house. I was unsure if this device could do anything for my son’s condition. To complicate things even more, my son had a pacemaker and the manuals for the device mention pacemakers as a contraindication. I discussed the risks and therapeutic scenarios with the inventor, Rolf Binder, as well as Dr. Kessler in Germany, and based on their long-term experience, they both encouraged me to start Randy on it immediately, in concert with his Coumadin regimen.

​

My next step was to take Randy and the device to New York Medical College’s Westchester Pediatric Division to test the possibility of any interference with the pacemaker signals if introduced to the electromagnetic field from the instrument. After running various tests, the cardiologists confirmed there was NO change in the output signals of the pacemaker. This was the answer I had hoped for. I was free and clear to start him on it.

​

The majority of my protocol involved patient-specific frequencies, scanning his body and simultaneously applying these therapeutic frequencies, thereby opening up the interference fields I found (mostly in the heart, kidney and brain areas.) After 3 sessions, which took no longer than 15 minutes each, we obtained another INR. For the first time, his coagulation was within therapeutic levels. I knew I was on to something. Randy continued sessions twice a week. About a month later, the Echo-cardiogram revealed that the Thrombosis started to reduce in size. This meant the world to me. I had the proof that it was working on my own son. My excitement was only surpassed by my enormous sense of relief. This was a dream come true for me as a parent. We continued the sessions on a weekly basis for several months until the thrombus was less than half its original size. Dr. Fulton in Boston was thrilled with the results and suggested that I take Randy off the Coumadin. “Whatever you are doing, it is working”, Dr. Fulton said and we clearly steered away from any more talk about surgery.

​

My son has been doing very well ever since. I am so thankful that this product came into our lives. As I’m sure you can imagine, this experience has formed an indelible bond between ONDAMED and myself. I have become very passionate about the device’s ability. In the two years since, I have witnessed remarkable results like my own reported by physicians, therapists, and patients that have been utilizing this modality. Below is the full specifics of my son’s case:

​

5-yr Old Male Diagnosed with Thrombosis

Patient has pacemaker after open-heart surgery 3 years ago at Children’s hospital in Boston (Corrected L-transposition (exchanging major arteries and creating baffle to shunt blood to correct inflow in the atria, closure of VSD). In March of 2002, patient was diagnosed with a thrombus measuring 10mm x 0.9mm located on heart valve. He had been on an average of 2mg Coumadin for 2 months, but had not yet reached a therapeutic level, which was set between 2-3 (INR). His blood results came back as 1.75, 1.8, 3.8 and 4.2.

​

Head cardiologist David Fulton, M.D. Assistant Professor Harvard Medical Schools, was considering surgically removing the thrombus due to the non-responsiveness of the patient to Coumadin. To potentially avoid surgery, ONDAMED was added to the treatment of the anti-coagulant.

​

The ONDAMED frequencies were tested at Children’s Hospital at Westchester Medical Center, NY, for interference between pacemaker and ONDAMED frequencies. There were NO fluctuations of the pacemaker spikes. Three ONDAMED Sessions were administered within 4 days; Scanning and applying patient specific frequencies. The patient’s interference fields were noted in patient data sheet and were worked on with the patient-specific frequencies.  Another INR blood test was taken several days later and for the first time, he reached a therapeutic level of 2.7.

​

Two additional Biofeedback therapies were administered over the following 5 days: Patient-specific frequencies were used in conjunction with its preset programs, which were selected, based on patient’s strongest pulse feedback including Cardiovascular, Balancing of Antibiotics and Heart Energy Field presets. The following day, the patient had echo cardiogram done at Westchester Medical Center, NY, which showed reduction of the blood clot to 0.9mm x 0.6mm.

 

Patient continued the sessions weekly. Three weeks later another echo-cardiogram showed that the thrombosis had reduced to 0.6mm x 0.5mm. Patient received sessions every 2 weeks with individual frequencies and pre-set programs. 3 months later, patient’s thrombosis was barely visible on the echo-cardiogram and patient was taken off the Coumadin medication. Patient successfully avoided having to go through open-heart surgery by adding the device to the existing treatment protocol. It acted as a facilitator, helping the patient with the cell detoxification and thereby increasing the absorption of Coumadin.  According to pediatric cardiologist Aaron Levine, M.D. Children’s Hospital at Westchester Medical Center, who stated in his letter dated October 2003 to the patient’s pediatrician “The thrombus as described in previous letters by Dr. Woolf is not clearly seen at this examination”.

The patient remains in good health.